Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Protalix BioTherapeutics, Inc. Common Stock (PLX) has a market cap of $190.15M with year-over-year revenue growth of -18.5%. Net margin stands at 5.5%. The stock trades at a P/E ratio of 64.9.
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, PLX posted revenue growth of -18.5% and trades at a P/E of 64.9.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.